Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression

References

• Coresh J. Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005; 16(1): 180–188.
   PubMed Web of Science ®Google Scholar
• Muntner P, Coresh J, Powe NR, Klag MJ. Contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol. 2003; 14(6): 1568–1577.
   Google Scholar
• Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001; 12(12): 2753–2758.
   PubMedGoogle Scholar
• National Kidney Foundation. Kidney Disease Quality Outcomes Initiative. 2000 Updates, http://www.kidney.org/professionals/kdoqi/guide-lines_ckd/toc.htm. Accessed May 9, 2007.
   Google Scholar
• Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983; 1(8335): 1175–1179.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. Collaborative Study Group. N Engl J Mcd. 1993; 329(20): 1456–1462.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12): 870–878.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D Keane WF, Mitch WE, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001(12); 345: 861–869.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12): 851–860.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect ofblood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288(19): 2421–2431.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004; 110(8): 921–927.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007; 49(1): 12–26.
   PubMed Web of Science ®Google Scholar
• Hollenberg K, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998; 32(3): 387–392.
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999; 82(1): 57–61.
   PubMed Web of Science ®Google Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003; 14(7): 1738–1747.
   PubMed Web of Science ®Google Scholar
• Barker TA, Massett MP, Korshunov VA, Mohan AM, Kennedy AJ, Berk BC. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Hypertension. 2006; 48(5): 942–949.
   Google Scholar
• Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111(8): 1012–1018.
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370(9583): 221–229.
   PubMed Web of Science ®Google Scholar
• Azizi M, Ménard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15(12): 3126–3133.
   Google Scholar
• Raij L. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens. 2005; 18(4 pt 2): 95S–99S.
   Google Scholar
• White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003; 41(5): 1021–1026.
   PubMed Web of Science ®Google Scholar
• Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006; 29(4): 211–216.
   Google Scholar
• Samuelsson O, Wilhelmsen L, Pennert K, Berglund G. Prognostic factors in treated hypertension. J Hypertens Suppl. 1985; 3(3): S497–S500.
   Google Scholar
• Almgren T, Persson B, Wilhelmsen L, et al. Stroke and coronary heart disease in treated hypertension—a prospective cohort study over three decades. J Intern Med. 2005; 257(6): 496–502.
   Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342(3): 145–153.
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). EUROPA Investigators. Lancet. 2003(9386); 362: 782–788.
   PubMed Web of Science ®Google Scholar
• Zandbergen AA, Vogt L, de Zeeuw D, et al. Change in albuminuria is predictive of cardiovascular outcome in normotensive patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2007; 30(12): 3119–3121.
   Google Scholar
• Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004; 6(7): 937–945.
   PubMedGoogle Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angioten-sin-converting enzyme inhibitors; the CHARM-Added trial. Lancet. 2003; 362(9386): 767–771.
   PubMed Web of Science ®Google Scholar
• McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. RESOLVD Pilot Study Investigators. Circulation. 1999; 100(10): 1056–1064.
   PubMed Web of Science ®Google Scholar
• McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, Captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006; 47(4): 726–733.
   Google Scholar
• Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996; 156(3): 286–289.
   PubMedGoogle Scholar
• Elung-Jensen T, Heisterberg J, Sonne J, et al. Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. Eur J Clin Pharmacol. 2005(2); 61: 87–96.
   PubMed Web of Science ®Google Scholar
• Bakris G, Burgess E, Weir M, et al. Comparative long-term effects of two AT1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial [abstract], J Clin Hypertens (Greenwich). 2007; 9(suppl A): A5.
   Google Scholar
• Barnett AH, Bain SC, Bouter P, et al; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy New Engl J Med. 2004; 351(19): 1952–1961.
   PubMed Web of Science ®Google Scholar
• Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol. 2004; 24(3): 340–345.
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007; 25(9): 1921–1926.
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminura, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321 (7274): 1440–1444.
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003; 14(4): 992–999.
   Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme Inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003(9354); 361: 117–124.
   Google Scholar
• Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002; 25(1): 95–100.
   Google Scholar
• Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol. 2006; 26(6): 629, 632.
   Google Scholar
• Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007; 72(7): 879–885.
   PubMed Web of Science ®Google Scholar
• Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issues. Semin Nephrol. 2004; 24(2): 168–175.
   PubMed Web of Science ®Google Scholar
• Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006; 24(2): 403 408.
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease ONTARGET/TRANSCEND) trials. ONTAR-GETATRANSCEND Investigators. Am Heart J. 2004; 148(1): 52–61.
   PubMed Web of Science ®Google Scholar
• KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49(2 Suppl 2): S12–S154.
   Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252.
   PubMed Web of Science ®Google Scholar